{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:43:25Z","timestamp":1792813405757,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2022-0086"],"award-info":[{"award-number":["6-2022-0086"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Glycopeptides for ampicillin-susceptible <jats:italic>Enterococcus faecalis\/faecium<\/jats:italic> bacteremia are readily prescribed depending on the severity of the condition. However, there is limited data on the outcomes of glycopeptide use compared to ampicillin-containing regimens for ampicillin-susceptible <jats:italic>E. faecalis\/faecium<\/jats:italic> bacteremia. From an antibiotic stewardship perspective, it is important to determine whether the use of glycopeptides is associated with improved clinical outcomes in patients with ampicillin-susceptible <jats:italic>E. faecalis\/faecium<\/jats:italic> bacteremia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study was conducted at a university-affiliated hospital between January 2010 and September 2019. We collected data from patients with positive blood cultures for <jats:italic>Enterococcus<\/jats:italic> species isolates. The clinical data of patients who received ampicillin-containing regimens or glycopeptides as definitive therapy for ampicillin-susceptible <jats:italic>E. faecalis\/faecium<\/jats:italic> bacteremia were reviewed. Multivariate logistic regression analysis was performed to identify risk factors for 28-day mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ampicillin-susceptible <jats:italic>E. faecalis\/faecium<\/jats:italic> accounted for 41.2% (557\/1,353) of enterococcal bacteremia cases during the study period. A total of 127 patients who received ampicillin-containing regimens (<jats:italic>N<\/jats:italic>\u2009=\u200956) or glycopeptides (<jats:italic>N<\/jats:italic>\u2009=\u200971) as definitive therapy were included in the analysis. The 28-day mortality rate was higher in patients treated with glycopeptides (19.7%) than in those treated with ampicillin-containing regimens (3.6%) (<jats:italic>p<\/jats:italic>\u2009=\u20090.006). However, in the multivariate model, antibiotic choice was not an independent predictor of 28-day mortality (adjusted OR, 3.7; 95% CI, 0.6\u201323.6).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Glycopeptide use was not associated with improved mortality in patients with ampicillin-susceptible <jats:italic>E. faecalis\/faecium<\/jats:italic> bacteremia. This study provides insights to reduce the inappropriate use of glycopeptides in ampicillin-susceptible <jats:italic>E. faecalis\/faecium<\/jats:italic> bacteremia treatment and promote antimicrobial stewardship.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09824-w","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:02:16Z","timestamp":1725274936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical outcome of ampicillin or ampicillin\/sulbactam versus glycopeptides in ampicillin-susceptible Enterococcus faecalis\/faecium bacteremia: a 10-year retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6402-4082","authenticated-orcid":false,"given":"Yeol Jung","family":"Seong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-6905","authenticated-orcid":false,"given":"Je Eun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0574-0840","authenticated-orcid":false,"given":"Eugene","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7008-0497","authenticated-orcid":false,"given":"Eun Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6548-1939","authenticated-orcid":false,"given":"Jung Yeon","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-3101","authenticated-orcid":false,"given":"Young Hwa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-7906","authenticated-orcid":false,"given":"Yong Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"9824_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrmicro2761","volume":"10","author":"CA Arias","year":"2012","unstructured":"Arias CA, Murray BE. The rise of the Enterococcus: beyond Vancomycin resistance. Nat Rev Microbiol. 2012;10:266\u201378.","journal-title":"Nat Rev Microbiol"},{"key":"9824_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jinf.2005.07.011","volume":"52","author":"CH Poh","year":"2006","unstructured":"Poh CH, Oh HML, Tan AL. Epidemiology and clinical outcome of enterococcal bacteraemia in an acute care hospital. J Infect. 2006;52:383\u20136.","journal-title":"J Infect"},{"key":"9824_CR3","doi-asserted-by":"crossref","unstructured":"Fiore E, Van Tyne D, Gilmore MS. Pathogenicity of enterococci. Microbiol Spectr. 2019;7.","DOI":"10.1128\/microbiolspec.GPP3-0053-2018"},{"key":"9824_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309\u201317.","journal-title":"Clin Infect Dis"},{"key":"9824_CR5","doi-asserted-by":"publisher","first-page":"e170322187568","DOI":"10.2174\/1871526520999201103191829","volume":"22","author":"S Jafari","year":"2022","unstructured":"Jafari S, Abdollahi A, Sabahi M, Salehi M, Asadollahi-Amin A, Hasannezhad M, et al. An update to enterococcal bacteremia: epidemiology, resistance, and outcome. Infect Disord Drug Targets. 2022;22:e170322187568.","journal-title":"Infect Disord Drug Targets"},{"key":"9824_CR6","doi-asserted-by":"crossref","unstructured":"Kim D, Lee H, Yoon EJ, Hong JS, Shin JH, Uh Y et al. Prospective observational study of the clinical prognoses of patients with bloodstream infections caused by ampicillin-susceptible but penicillin-resistant Enterococcus faecalis. Antimicrob Agents Chemother. 2019;63.","DOI":"10.1128\/AAC.00291-19"},{"key":"9824_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/0897190017751208","volume":"32","author":"JM Fletcher","year":"2019","unstructured":"Fletcher JM, Kram SJ, Sarubbi CB, Anderson DJ, Kram BL. Effectiveness of Vancomycin or beta-lactam therapy in ampicillin-susceptible Enterococcus spp. bloodstream infections. J Pharm Pract. 2019;32:375\u201381.","journal-title":"J Pharm Pract"},{"key":"9824_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/1469-0691.12236","volume":"20","author":"M Pinholt","year":"2014","unstructured":"Pinholt M, Ostergaard C, Arpi M, Bruum NE, Sch\u00f8nheyder HC, Gradel KO, et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006\u20132009: a population-based cohort study. Clin Microbiol Infect. 2014;20:145\u201351.","journal-title":"Clin Microbiol Infect"},{"key":"9824_CR9","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1093\/jac\/dku107","volume":"69","author":"H Foo","year":"2014","unstructured":"Foo H, Chater M, Maley M, van Hal SJ. Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia. J Antimicrob Chemother. 2014;69:2252\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"9824_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00000441-196912000-00006","volume":"258","author":"P Toala","year":"1969","unstructured":"Toala P, McDonald A, Wilcox C, Finland M. Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences. Am J Med Sci. 1969;258:416\u201330.","journal-title":"Am J Med Sci"},{"key":"9824_CR11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0002-9343(89)80611-4","volume":"87","author":"M Hilf","year":"1989","unstructured":"Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87:540\u20136.","journal-title":"Am J Med"},{"key":"9824_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","volume":"115","author":"JW Chow","year":"1991","unstructured":"Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585\u201390.","journal-title":"Ann Intern Med"},{"key":"9824_CR13","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1128\/AAC.36.12.2639","volume":"36","author":"JA Korvick","year":"1992","unstructured":"Korvick JA, Bryan CS, Farber B, Beam TR, Schenfeld L, Muder RR, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother. 1992;36:2639\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"9824_CR14","doi-asserted-by":"crossref","unstructured":"Hemapanpairoa J, Changpradub D, Santimaleeworagun W. Clinical impact of Vancomycin treatment in ampicillin-susceptible enterococci bloodstream infections. Antibiot (Basel). 2022;11.","DOI":"10.3390\/antibiotics11121698"},{"key":"9824_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1086\/510386","volume":"44","author":"ME Stryjewski","year":"2007","unstructured":"Stryjewski ME, Szczech LA, Benjamin DK, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of Vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44:190\u20136.","journal-title":"Clin Infect Dis"},{"key":"9824_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1128\/AAC.00700-07","volume":"52","author":"SH Kim","year":"2008","unstructured":"Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, et al. Outcome of Vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52:192\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"9824_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/1471-2334-11-279","volume":"11","author":"ML Schweizer","year":"2011","unstructured":"Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, et al. Comparative effectiveness of nafcillin or cefazolin versus Vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11:279.","journal-title":"BMC Infect Dis"},{"key":"9824_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10096-006-0096-0","volume":"25","author":"R Khatib","year":"2006","unstructured":"Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2006;25:181\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"9824_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/cid\/civ308","volume":"61","author":"JS McDanel","year":"2015","unstructured":"McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, et al. Comparative effectiveness of beta-lactams versus Vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61:361\u20137.","journal-title":"Clin Infect Dis"},{"key":"9824_CR20","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/jac\/dkl355","volume":"58","author":"ML Fern\u00e1ndez Guerrero","year":"2006","unstructured":"Fern\u00e1ndez Guerrero ML, de G\u00f3rgolas M. Comparative activity of Cloxacillin and Vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis. J Antimicrob Chemother. 2006;58:1066\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"9824_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/0974-777X.93758","volume":"4","author":"V Moses","year":"2012","unstructured":"Moses V, Jerobin J, Nair A, Sathyendara S, Balaji V, George IA, et al. Enterococcal bacteremia is associated with prolonged stay in the medical Intensive Care Unit. J Glob Infect Dis. 2012;4:26\u201330.","journal-title":"J Glob Infect Dis"},{"key":"9824_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10096-009-0830-5","volume":"29","author":"SJ McBride","year":"2010","unstructured":"McBride SJ, Upton A, Roberts SA. Clinical characteristics and outcomes of patients with Vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia\u2013a five-year retrospective review. Eur J Clin Microbiol Infect Dis. 2010;29:107\u201314.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"9824_CR23","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/j.1469-0691.2010.03394.x","volume":"17","author":"M Suppli","year":"2011","unstructured":"Suppli M, Aabenhus R, Harboe ZB, Andersen LP, Tvede M, Jensen JU. Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect. 2011;17:1078\u201383.","journal-title":"Clin Microbiol Infect"},{"key":"9824_CR24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ijid.2022.06.029","volume":"122","author":"S Ha","year":"2022","unstructured":"Ha S, Huh K, Chung DR, Ko JH, Cho SY, Huh HJ, et al. Efficacy of teicoplanin in bloodstream infections caused by Enterococcus faecium: posthoc analysis of a nationwide surveillance. Int J Infect Dis. 2022;122:506\u201313.","journal-title":"Int J Infect Dis"},{"key":"9824_CR25","doi-asserted-by":"crossref","unstructured":"Uda A, Shigemura K, Kitagawa K, Osawa K, Onuma K, Yan Y et al. Risk factors for the acquisition of Enterococcus faecium infection and mortality in patients with enterococcal bacteremia: a 5-year retrospective analysis in a tertiary care University Hospital. Antibiot (Basel). 2021;10.","DOI":"10.3390\/antibiotics10010064"},{"key":"9824_CR26","first-page":"119","volume":"3","author":"S Calik","year":"2019","unstructured":"Calik S, Ari A, Okur O, Tosun S, Yis R. Nosocomial enterococcal bacteremia: predictors of resistance and mortality. Eurasian J Med Invest. 2019;3:119\u201326.","journal-title":"Eurasian J Med Invest"},{"key":"9824_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jiac.2015.04.001","volume":"21","author":"Y Hamada","year":"2015","unstructured":"Hamada Y, Magarifuchi H, Oho M, Kusaba K, Nagasawa Z, Fukuoka M, et al. Clinical features of enterococcal bacteremia due to ampicillin-susceptible and ampicillin-resistant enterococci: an eight-year retrospective comparison study. J Infect Chemother. 2015;21:527\u201330.","journal-title":"J Infect Chemother"},{"key":"9824_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ijantimicag.2019.03.023","volume":"53","author":"N Petersiel","year":"2019","unstructured":"Petersiel N, Bitterman R, Manaa A, Nashashibi L, Moskovich O, Geffen Y, et al. \u03b2-lactam antibiotics vs. Vancomycin for the early treatment of enterococcal bacteraemia: a retrospective cohort study. Int J Antimicrob Agents. 2019;53:761\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"9824_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijantimicag.2018.03.001","volume":"52","author":"CJP Economou","year":"2018","unstructured":"Economou CJP, Kielstein JT, Czock D, Xie J, Field J, Richards B, et al. Population pharmacokinetics of Vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. Int J Antimicrob Agents. 2018;52:151\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"9824_CR30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","volume":"29","author":"MN Jeffres","year":"2007","unstructured":"Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with Vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29:1107\u201315.","journal-title":"Clin Ther"},{"key":"9824_CR31","unstructured":"Bruniera FR, Ferreira FM, Saviolli LR, Bacci MR, Feder D et al. da Luz Gon\u00e7alves Pedreira MD,. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci. 2015;19:694\u2013700."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09824-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09824-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09824-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:02:32Z","timestamp":1725274952000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09824-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9824"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09824-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Institutional Review Board of the Ajou University Medical Center (AJOUIRB-MDB-2021-708). Informed consent to participate was waived by the Institutional Review Board of the Ajou University Medical Center because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"906"}}